Circulating free mitochondrial DNA concentration and its association with erlotinib treatment in patients with adenocarcinoma of the lung

Oncology Letters

Volumn 7, Issue 6, 2014, Pages 2180-2184

  Huang, Chu Yun ^a   Chen, Yuh Min ^a,b   Wu, Chieh Hung ^a   Tsai, Chun Ming ^a   Lee, Yu Chin ^a   Perng, Reury Perng ^a   Whang Peng, Jacqueline ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Epidermal growth factor receptor; Lung cancer; Mitochondria; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MITOCHONDRIAL DNA;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATION; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

EID: 84898874460     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2006     Document Type: Article

References (26)

1. Wu CH, Fan WC, Chen YM, Chou KT, Shih JF, Tsai CM, et al: Second-line therapy for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effective as for younger patients. J Thorac Oncol 5: 376-379, 2010.
2. Paci M, Maramotti S, Bellesia E, Formisano D, Albertazzi L, Ricchetti T, et al: Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer 64: 92-97, 2009.
3. Pathak AK, Bhutani M, Kumar S, Mohan A and Guleria R: Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem 52: 1833-1842, 2006.
4. Cheng C, Omura-Minamisawa M, Kang Y, Hara T, Koike I and Inoue T: Quantification of circulating cell-free DNA in the plasma of cancer patients during radiation therapy. Cancer Sci 100: 303-309, 2009.
5. Mancini M, Anderson BO, Caldwell E, Sedghinasab M, Paty PB and Hockenbery DM: Mitochondrial proliferation and paradoxical membrane depolarization during terminal differentiation and apoptosis in a human colon carcinoma cell line. J Cell Biol 138: 449-469, 1997.
6. Ellinger J, Müller SC, Wernert N, von Ruecker A and Bastian PJ: Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy. BJU Int 102: 628-632, 2008.
7. Zhang R, Shao F, Wu X and Ying K: Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: A meta-analysis. Lung Cancer 69: 225-231, 2010.
8. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
9. Vassilakopoulos T, Troupis T, Sotiropoulou C, Zacharatos P, Katsaounou P, Parthenis D, et al: Diagnostic and prognostic significance of squamous cell carcinoma antigen in non-small cell lung cancer. Lung Cancer 32: 137-144, 2001.
10. Suemitsu R, Yoshino I, Tomiyasu M, Fukuyama S, Okamoto T and Maehara Y: Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer. Surg Today 34: 896-901, 2004.
11. Kulpa J, Wójcik E, Reinfuss M and Kolodziejski L: Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 48: 1931-1937, 2002.
12. Sozzi G, Conte D, Mariani L, et al: Analysis of circulating DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 61: 4675-4678, 2001.
13. Sozzi G, Conte D, Leon M, et al: Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21: 3902-3908, 2003.
14. Gai S, Fidler C, Lo YM, et al: Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR. Br J Cancer 90: 1211-1215, 2004.
15. Flamini E, Mercatali L, Nanni O, et al: Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin Cancer Res 12: 6985-6988, 2006.
16. Ziegler A, Zangemeister-Wittke U and Stahel RA: Circulating DNA a new diagnostic gold mine? Cancer Treat Rev 28: 255-271, 2002.
17. Gormally E, Caboux E, Vineis P and Hainaut P: Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 635: 105-117, 2007.
18. Laktionov PP, Tamkovich SN, Rykova EY, Bryzgunova OE, Starikov AV, Kuznetsova NP, et al: Extracellular circulating nucleic acids in human plasma in health and disease. Nucleosides Nucleotides Nucleic Acids 23: 879-883, 2004.
19. Antonatos D, Patsilinakos S, Spanodimos S, Korkonikitas P and Tsigas D: Cell-free DNA levels as a prognostic marker in acute myocardial infarction. Ann NY Acad Sci 1075: 278-281, 2006.
20. Pathak AK, Bhutani M, Kumar S, Mohan A and Guleria R: Circulating free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem 52: 1833-1842, 2006.
21. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239-246, 2012.
22. Punnoose EA, Atwal S, Liu W, et al: Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res 18: 2391-2401, 2012.
23. Penta JS, Johnson FM, Wachsman JT and Copeland WC: Mitochondrial DNA in human malignancy. Mutat Res 488: 119-133, 2001.
24. Jerónimo C, Nomoto S, Caballero OL, Usadel H, Henrique R, Varzim G, et al: Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene 20: 5195-5198, 2001.
25. Leon SA, Shapiro B, Sklaroff DM and Yaros MJ: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37: 646-650, 1977.
26. Kumar S, Guleria R, Singh V, et al: Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer. Eur Respir J 36: 885-892, 2010.